15 assets in Prader-Willi Syndrome

Therapeutic assets addressing Prader-Willi Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Serostim Prader-Willi Syndrome	Corporacion Parc Tauli	P4	BBB (77)
Oxytocin Prader-Willi Syndrome	University Hospital, Toulouse	P2/3	BBB (76)
Dccr Prader-Willi Syndrome	Soleno Therapeutics, Inc.	P3	BB (70)
Tirzepatide Prader-Willi Syndrome	Grace Kim	P4	BB (65)
Pitolisant Prader-Willi Syndrome	Harmony Biosciences Management, Inc.	P3	BB (64)
Ard-101 Prader-Willi Syndrome	Aardvark Therapeutics, Inc.	P3	B (60)
Csti-500 Prader-Willi Syndrome	ConSynance Therapeutics	P2	B (60)
rad011 Prader-Willi Syndrome	Radius Pharmaceuticals, Inc.	P3	B (60)
Nbt-Nm108 Prader-Willi Syndrome	Rutgers, The State University of New Jersey	P2	B (57)
Rgh-706 Prader-Willi Syndrome	Gedeon Richter Plc.	P2	B (57)
Setmelanotide Prader-Willi Syndrome	Rhythm Pharmaceuticals, Inc.	P2	B (57)
Bmb-101 Prader-Willi Syndrome	Bright Minds Biosciences Pty Ltd	P2	CCC (53)
Cyclo(-L-Glycyl-L-2-Allylproline) Prader-Willi Syndrome	Neuren Pharmaceuticals Limited	P2	CCC (53)
RM-718 Prader-Willi Syndrome	Rhythm Pharmaceuticals, Inc.	P1/2	CC (47)